Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study.
Krzysztof TomasiewiczAnna PiekarskaJustyna Stempkowska-RejekSylwia SerafińskaAleksandra GawkowskaMiłosz ParczewskiJolanta Niścigorska-OlsenTadeusz W ŁapińskiDorota Zarębska-MichalukJustyna Dominika KowalskaAndrzej HorbanRobert FlisiakPublished in: Expert review of anti-infective therapy (2020)
Tocilizumab can control the symptoms of severe COVID-19 by reducing the inflammatory response and rapidly improves the clinical status in most patients.
Keyphrases
- coronavirus disease
- inflammatory response
- sars cov
- rheumatoid arthritis
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- early onset
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- prognostic factors
- lipopolysaccharide induced
- depressive symptoms
- respiratory syndrome coronavirus
- drug induced
- lps induced
- sleep quality